The outlook for full year 2025 remains unchanged at flat to 1% currency-neutral revenue growth, consistent with the Q2 update. Margins guidance is also unchanged. Q3 reported a slight revenue and ...

On October 29, 2025, Bio-Rad Laboratories reported third-quarter earnings with sales of US$653 million and a net loss of US$341.9 million, while also completing a major share repurchase and announcing ...

Biodesix has expanded its collaboration with Bio-Rad for the development and clinical validation of in vitro diagnostic (IVD) ...

Biodesix expands its Bio-Rad partnership to validate ddPCR cancer assays, starting with ESR1 mutation testing in breast ...

Investing.com -- Biodesix (NYSE:BDSX) stock rose 10% Wednesday after the diagnostics solutions company announced an expanded partnership agreement with Bio-Rad Laboratories to develop high complexity ...

Biodesix, Inc. (NYSE: BDSX), a leading diagnostics solutions company, today announced the signing of an expanded partnership agreement under which Biodesix will ...

Speaker panel will include collaborative case study presentations from strategic partners: Memorial Sloan Kettering Cancer Center, Bio-Rad Laboratories, and Thermo Fisher Scientific ...

Biodesix, Inc has expanded its long-standing collaboration with Bio-Rad Laboratories to co-develop and clinically validate ...

The Colorado firm is expanding its partnerships, outreach efforts, technology applications, and sales force for its oncology screening and monitoring test business.

Bio-Rad Laboratories (BIO) has expanded its collaboration with Biodesix, aiming to clinically validate and pursue regulatory approval for cancer biomarker diagnostic assays. The partnership highlights ...